Compare Heron Therapeutics Inc (HRTX) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs QUALCOMM, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while QUALCOMM, Inc. trades at $175.5 (market cap $187.95B). The key difference: QUALCOMM, Inc. is far larger — about 2763.6× Heron Therapeutics Inc's market cap, and QUALCOMM, Inc. pays a 2.09% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and QUALCOMM, Inc. for 87 Days on average.
| HRTX | QCOM | |
|---|---|---|
Market Cap | $68.01M | $187.95B |
Volume | 1,891,941 | 9,535,042 |
Sector | Health | Technology |
52-Week High | $1.49 | $251.10 |
52-Week Low | $0.27 | $124.07 |
Typical Hold Time | 35 Days | 87 Days |
Enterprise Value | $174.75M | $194.92B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.4061, up 4.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics (-22.52% net margin), analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX faces significant fundamental challenges with consistent losses and negative ROE, though revenue stability provides some foundation. The strong analyst support suggests potential upside if operational improvements materialize, but high execution risk and cash flow concerns warrant caution for investors seeking near-term profitability.
Qualcomm (QCOM) trades at $176.01, down 0.59% on the day, with a bearish technical signal and key support at $173. The company reported mixed Q2 2026 earnings, missing EPS estimates, but maintains strong profitability with a 21.01% net margin and 33.75% ROE. Recent news highlights a transformative $60 billion AI partnership with Amazon, boosting sentiment despite near-term volatility.
QCOM presents a compelling risk-reward profile with a consensus price target of $204.48, implying 16% upside. Strengths include robust cash flow and diversification into AI/data centers, but risks involve execution on new initiatives and dependence on smartphone markets. Analyst consensus leans Hold, reflecting cautious optimism amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
